Getagraph.com logo
NASDAQ Composite: ( -0.07%) 16 686
S&P 500 Futures
(0.10%) 5 332.75 points
Dow Jones Futures
(0.02%) 40 146 points
Nasdaq Futures
(0.17%) 18 667 points
Oil
(0.10%) $80.14
Gas
(0.53%) $2.64
Gold
(1.12%) $2 444.50
Silver
(2.90%) $32.17
Platinum
(0.21%) $1 092.30
USD/EUR
(0.00%) $0.920
USD/NOK
(-0.05%) $10.67
USD/GBP
(0.06%) $0.788
USD/RUB
(0.28%) $91.23

Realtime updates for Tango Therapeutics, Inc. [TNGX]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
60.00%
return 5.74%
SELL
25.00%
return 10.06%
Last Updated17 May 2024 @ 16:00
25% discount on Stockinvest.us - Use code: Podcast

-3.47% $ 7.52

SELL 138951 min ago

@ $11.71

Issued: 13 Feb 2024 @ 15:42

Return: -35.78%

Previous signal: Feb 13 - 09:30

Previous signal: Buy

Return: -1.76 %

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 16:00):

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions...

Stats
Today's Volume 414 937
Average Volume 596 458
Market Cap 803.48M
EPS $0 ( 2024-05-14 )
Next earnings date ( $-0.310 ) 2024-06-05
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -6.77
ATR14 $0.0100 (0.13%)
Insider Trading
Date Person Action Amount type
2024-05-01 Mva Investors, Llc Sell 75 000 Common Stock
2024-05-02 Mva Investors, Llc Sell 75 000 Common Stock
2024-05-03 Mva Investors, Llc Sell 60 000 Common Stock
2024-02-20 Third Rock Ventures Iv, L.p. Sell 162 500 Common Stock
2024-02-06 Weber Barbara Sell 4 681 Common Stock
INSIDER POWER
86.98
Last 93 transactions
Buy: 16 052 308 | Sell: 875 313

Volume Correlation

Long: 0.06 (neutral)
Short: 0.89 (strong)
Signal:(74.509) Same movement expected

Tango Therapeutics, Inc. Correlation

10 Most Positive Correlations
DRUG0.943
INTA0.927
NEPH0.924
ZS0.92
GTEC0.919
TACT0.919
AEI0.915
CPSH0.911
ELTK0.911
WKME0.906
10 Most Negative Correlations
BZ-0.937
DXPE-0.925
LFMDP-0.914
GTLS-0.913
IPKW-0.913
KNTK-0.912
FTXN-0.91
EUFN-0.907
BNR-0.907
EBAY-0.904

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Tango Therapeutics, Inc. Correlation - Currency/Commodity

The country flag 0.16
( neutral )
The country flag -0.05
( neutral )
The country flag 0.00
( neutral )
The country flag 0.25
( neutral )
The country flag 0.49
( neutral )
The country flag -0.15
( neutral )

Tango Therapeutics, Inc. Financials

Annual 2023
Revenue: $36.53M
Gross Profit: $34.11M (93.39 %)
EPS: $-1.080
FY 2023
Revenue: $36.53M
Gross Profit: $34.11M (93.39 %)
EPS: $-1.080
FY 2022
Revenue: $24.86M
Gross Profit: $20.83M (83.80 %)
EPS: $-1.230
FY 2021
Revenue: $37.04M
Gross Profit: $37.04M (100.00 %)
EPS: $-3.49

Financial Reports:

No articles found.

Tango Therapeutics, Inc. Options Data

Calls

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Puts

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Tango Therapeutics, Inc.

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators